Table 2.

Clinical presentation and outcomes

Pathogenic yeast (%)
C. parapsilosis	50
Candida species	28.6
C. albicans	21.4
Peritonitis risk factors [number of patients (%)]
Previous bacterial peritonitis	11 (78.6)
Previous antibiotic treatment	14 (100)
Bowel-source infection (e.g. diverticulitis)	1 (7)
Gynaecological-source infection	0
None	3 (21.4)
Peritoneal effluent cell count (N/MMC), mean ± SD	2688 ± 5197
Primary FP	3 patients (35 %)
Secondary FP	11 patients (75 %)
Treatment [number of patients (%)]
Fluconazole	13 (92.9)
Voriconazole	1 (7.1)
Treatment duration (days), mean ± SD	22 ± 14
Fluconazole	200 mg/48 h
Voriconazole	400 mg/24 h
Hospitalization (days), mean ± SD	27 ± 19
Outcome [number of patients (%)]
Death	2 (14)
Tenckhoff removal	12 (86)
Shift to haemodialysis	11 (79)
PD resumption	1 (7)

N/MMC, number per cubic millimeter.